SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

PF-9363

Item No. 37778

CAS Registry No.: 2569009-58-9
Formal Name: 2,6-dimethoxy-N-[4-methoxy-6-(1H-pyrazol-1-ylmethyl)-1,2-benzisoxazol-3-yl]-benzenesulfonamide
Synonym: CTx-648
MF: $C_{20}H_{20}N_4O_6S$
FW: 444.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF-9363 is supplied as a solid. A stock solution may be made by dissolving the PF-9363 in the solvent of choice, which should be purged with an inert gas. PF-9363 is soluble in the organic solvent DMSO.

Description

PF-9363 is an inhibitor of lysine acetyltransferase 6A (KAT6A), also known as monocytic leukemia zinc finger protein (MOZ) and KAT6B, also known as MOZ-related factor (MORF; K_is = 0.27 and 2.4 nM, respectively).[1] It is selective for KAT6A and KAT6B over KAT7, KAT5, and KAT8 (K_is = 70, 420, and 670 nM, respectively). PF-9363 reduces the proliferation of, and the levels of acetylation of histone 3 lysine 23 (H3K23Ac) and lysine 14 (H3K14Ac) in, ZR-75-1 breast epithelial carcinoma cells (IC_{50}s = 0.37, 0.85, and 120 nM, respectively). It reduces tumor levels of H3K23Ac and tumor volume without affecting body weight in a ZR-75-1 breast cancer mouse xenograft model when administered at doses of 0.03, 03, or 5 mg/kg per day. PF-9363 (1 mg/kg per day) reduces tumor volume and increases survival in a patient-derived xenograft (PDX) mouse model of breast cancer.

Reference

1. Sharma, S., Chung, C.-Y., Uryu, S., *et al.* Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. *Cell Chem. Biol.* **30** (2023).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM